Meeting
2020 ASCO Virtual Scientific Program
Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
W. Kevin Kelly
Thomas Jefferson University, Philadelphia, PA
W. Kevin Kelly , Daniel Costin Danila , William Jeffery Edenfield , Rahul Raj Aggarwal , Daniel Peter Petrylak , A. Oliver Sartor , Christopher Joseph Sumey , Tanya B. Dorff , Evan Y. Yu , Nabil Adra , David Michael Waterhouse , Andrew J. Armstrong , Lisa Horvath , David William Pook , Leonard Joseph Appleman , Aubrey Lau , Mark Salvati , Hosein Kouros-Mehr
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT04221542
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS5589)
DOI
10.1200/JCO.2020.38.15_suppl.TPS5589
Abstract #
TPS5589
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: William Kevin Kelly
Poster
2022 ASCO Annual Meeting
A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Costin Danila
First Author: Mark T. Fleming
Poster
2024 ASCO Genitourinary Cancers Symposium
PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.
First Author: Arun Azad